Potential involvement of the interleukin-18 pathway in schizophrenia

Journal of Psychiatric Research

Volumn 74, Issue , 2016, Pages 10-16

  Xu, Yong ^a   Yue, Weihua ^b,c   Shugart, Yin Yao ^d   Yuan, Jianmin ^e   Wang, Guoqiang ^e   Wang, Harold Z ^d   Lehrman, Benjamin ^d   Zhang, Fuquan ^e   Zhang, Dai ^b,c,f  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^c BEIJING HOSPITAL   (China)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e NANJING MEDICAL UNIVERSITY   (China)

^f PEKING UNIVERSITY   (China)

Author keywords

IL18; IL18R1; Schizophrenia

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 18 RECEPTOR ALPHA; IL18R1 PROTEIN, HUMAN; IL18RAP PROTEIN, HUMAN; INTERLEUKIN 18 RECEPTOR BETA;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; BLOOD; CHILD; CHINA; FEMALE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MALE;

ADOLESCENT; CHILD; CHINA; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERLEUKIN-18; INTERLEUKIN-18 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-18 RECEPTOR BETA SUBUNIT; MALE; QUANTITATIVE TRAIT LOCI; SCHIZOPHRENIA;

EID: 84958058655     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.12.013     Document Type: Article

References (72)

1. Al-Hakeim H.K., Al-Rammahi D.A., Al-Dujaili A.H. IL-6, IL-18, sIL-2R, and TNFalpha proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J. Affect. Disord. 2015, 182:106-114.
2. Alboni S., Cervia D., Sugama S., Conti B. Interleukin 18 in the CNS. J. Neuroinflammation 2010, 7:9.
3. Alboni S., Montanari C., Benatti C., Blom J.M., Simone M.L., Brunello N., et al. Constitutive and LPS-regulated expression of interleukin-18 receptor beta variants in the mouse brain. Brain Behav. Immun. 2011, 25:483-493.
4. Arolt V., Rothermundt M., Wandinger K.P., Kirchner H. Decreased in vitro production of interferon-gamma and interleukin-in whole blood of patients with schizophrenia during treatment. Mol. Psychiatry 2000, 5:150-158.
5. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
6. Bell J.T., Pai A.A., Pickrell J.K., Gaffney D.J., Pique-Regi R., Degner J.F., et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011, 12:R10.
7. Ben Achour S., Pascual O. Glia: the many ways to modulate synaptic plasticity. Neurochem. Int. 2010, 57:440-445.
8. Bergink V., Gibney S.M., Drexhage H.A. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol. Psychiatry 2014, 75:324-331.
9. Billiau A., Heremans H., Vermeire K., Matthys P. Immunomodulatory properties of interferon-gamma. An update. Ann. N. Y. Acad. Sci. 1998, 856:22-32.
10. Clemmensen L., Vernal D.L., Steinhausen H.C. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry 2012, 12:150.
11. Dinarello C.A. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr. 2006, 83. 447S-55S.
12. Dunn A.J., Wang J., Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv. Exp. Med. Biol. 1999, 461:117-127.
13. Favero F. RmiR.Hs.miRNA: Various Databases of MicroRNA Targets 2012, R package version 1.0.6.
14. Felderhoff-Mueser U., Schmidt O.I., Oberholzer A., Buhrer C., Stahel P.F. IL-18: a key player in neuroinflammation and neurodegeneration?. Trends Neurosci. 2005, 28:487-493.
15. Franceschini A., Szklarczyk D., Frankild S., Kuhn M., Simonovic M., Roth A., et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013, 41:D808-D815.
16. Gamazon E.R., Badner J.A., Cheng L., Zhang C., Zhang D., Cox N.J., et al. Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol. Psychiatry 2013, 18:340-346.
17. Gong Y., Wu C.N., Xu J., Feng G., Xing Q.H., Fu W., et al. Polymorphisms in microRNA target sites influence susceptibility to schizophrenia by altering the binding of miRNAs to their targets. Eur. Neuropsychopharmacol. 2013, 23:1182-1189.
18. Grossmann M., Nakamura Y., Grumont R., Gerondakis S. New insights into the roles of ReL/NF-kappa B transcription factors in immune function, hemopoiesis and human disease. Int. J. Biochem. Cell Biol. 1999, 31:1209-1219.
19. Grundberg E., Meduri E., Sandling J.K., Hedman A.K., Keildson S., Buil A., et al. Global analysis of DNA methylation variation in adipose tissue from twins reveals links to disease-associated variants in distal regulatory elements. Am. J. Hum. Genet. 2013, 93:876-890.
20. Harris L.W., Pietsch S., Cheng T.M., Schwarz E., Guest P.C., Bahn S. Comparison of peripheral and central schizophrenia biomarker profiles. PLoS One 2012, 7:e46368.
21. Hashimoto R., Ohi K., Yasuda Y., Fukumoto M., Yamamori H., Takahashi H., et al. Variants of the RELA gene are associated with schizophrenia and their startle responses. Neuropsychopharmacology 2011, 36:1921-1931.
22. Hebert S.S., De Strooper B. Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci. 2009, 32:199-206.
23. Hunsberger J.G., Austin D.R., Chen G., Manji H.K. MicroRNAs in mental health: from biological underpinnings to potential therapies. Neuromolecular Med. 2009, 11:173-182.
24. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 2003, 33 Suppl:245-254.
25. Kalina U., Ballas K., Koyama N., Kauschat D., Miething C., Arnemann J., et al. Genomic organization and regulation of the human interleukin-18 gene. Scand. J. Immunol. 2000, 52:525-530.
26. Kim H.J., Eom C.Y., Kwon J., Joo J., Lee S., Nah S.S., et al. Roles of interferon-gamma and its target genes in schizophrenia: proteomics-based reverse genetics from mouse to human. Proteomics 2012, 12:1815-1829.
27. Kirkpatrick B., Miller B.J. Inflammation and schizophrenia. Schizophr. Bull. 2013, 39:1174-1179.
28. Kneeland R.E., Fatemi S.H. Viral infection, inflammation and schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 42:35-48.
29. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am. J. Hum. Genet. 2003, 73:34-48.
30. Liou Y.J., Wang H.H., Lee M.T., Wang S.C., Chiang H.L., Chen C.C., et al. Genome-wide association study of treatment refractory schizophrenia in Han Chinese. PLoS One 2012, 7:e33598.
31. Lu L.X., Guo S.Q., Chen W., Li Q., Cheng J., Guo J.H. Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia. Di 1 Jun Yi Da Xue Xue Bao Acad. J. First Med. Coll. Pla 2004, 24:1251-1254.
32. Luo Y., He H., Zhang M., Huang X., Zhang J., Zhou Y., et al. Elevated serum levels of TNF-alpha, IL-and IL-18 in chronic schizophrenic patients. Schizophrenia Res. 2014, 159:556-557.
33. Mattson M.P., Culmsee C., Yu Z., Camandola S. Roles of nuclear factor kappaB in neuronal survival and plasticity. J. Neurochem. 2000, 74:443-456.
34. McCusker R.H., Kelley K.W. Immune-neural connections: how the immune system's response to infectious agents influences behavior. J. Exp. Biol. 2013, 216:84-98.
35. Messias E.L., Chen C.Y., Eaton W.W. Epidemiology of schizophrenia: review of findings and myths. Psychiatric Clin. N. Am. 2007, 30:323-338.
36. Meyer U. Developmental neuroinflammation and schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 42:20-34.
37. Miller B.H., Wahlestedt C. MicroRNA dysregulation in psychiatric disease. Brain Res. 2010, 1338:89-99.
38. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
39. Monje M.L., Toda H., Palmer T.D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
40. Muller N., Schwarz M.J. Immune system and schizophrenia. Curr. Immunol. Rev. 2010, 6:213-220.
41. Munder M., Mallo M., Eichmann K., Modolell M. Direct stimulation of macrophages by IL-12 and IL-18-bridge built on solid ground. Immunol. Lett. 2001, 75:159-160.
42. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder?. Br. Med. J. Clin. Res. Ed) 1987, 295:681-682.
43. Na K.S., Jung H.Y., Kim Y.K. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 48:277-286.
44. Palladino I., Salani F., Ciaramella A., Rubino I.A., Caltagirone C., Fagioli S., et al. Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia. J. Neuroinflammation 2012, 9:206.
45. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63:801-808.
46. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
47. Rapoport J.L., Giedd J.N., Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. Mol. Psychiatry 2012, 17:1228-1238.
48. Rasmussen H.B., Timm S., Wang A.G., Soeby K., Lublin H., Fenger M., et al. Association between the CCR5 32-bp deletion allele and late onset of schizophrenia. Am. J. Psychiatry 2006, 163:507-511.
49. Roussos P., Katsel P., Davis K.L., Giakoumaki S.G., Lencz T., Malhotra A.K., et al. Convergent findings for abnormalities of the NF-kappaB signaling pathway in schizophrenia. Neuropsychopharmacology 2013, 38:533-539.
50. Schmitz T., Chew L.J. Cytokines and myelination in the central nervous system. ScientificWorldJournal 2008, 8:1119-1147.
51. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004, 75:163-189.
52. Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13:2498-2504.
53. Shi S., Leites C., He D., Schwartz D., Moy W., Shi J., et al. MicroRNA-and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant. J. Biol. Chem. 2014, 289:13434-13444.
54. Shi W., Du J., Qi Y., Liang G., Wang T., Li S., et al. Aberrant expression of serum miRNAs in schizophrenia. J. Psychiatric Res. 2012, 46:198-204.
55. Shirts B.H., Wood J., Yolken R.H., Nimgaonkar V.L. Comprehensive evaluation of positional candidates in the IL-18 pathway reveals suggestive associations with schizophrenia and herpes virus seropositivity. Am. J. Med. Genet. Part B Neuropsychiatric Genet. 2008, 147:343-350.
56. Shoemaker R., Deng J., Wang W., Zhang K. Allele-specific methylation is prevalent and is contributed by CpG-SNPs in the human genome. Genome Res. 2010, 20:883-889.
57. Smyth A.M., Lawrie S.M. The neuroimmunology of schizophrenia. Clin. Psychopharmacol. Neurosci. 2013, 11:107-117.
58. Song X.Q., Lv L.X., Li W.Q., Hao Y.H., Zhao J.P. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol. Psychiatry 2009, 65:481-488.
59. Tanaka K.F., Shintani F., Fujii Y., Yagi G., Asai M. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res. 2000, 96:75-80.
60. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. General Psychiatry 1987, 44:660-669.
61. Welberg L. Neurodegenerative disorders: reconnect with microRNA. Nat. Rev. Neurosci. 2010, 11:74.
62. Wheeler R.D., Culhane A.C., Hall M.D., Pickering-Brown S., Rothwell N.J., Luheshi G.N. Detection of the interleukin 18 family in rat brain by RT-PCR. Brain Res. Mol. Brain Res. 2000, 77:290-293.
63. Wood S.J., Yucel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann. Acad. Med. Singap. 2009, 38. 396-6.
64. Woodroofe M.N. Cytokine production in the central nervous system. Neurology 1995, 45:S6-S10.
65. Xiu M.H., Chen da C., Wang D., Zhang K., Dong A., Tang W., et al. Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology. J. Psychiatric Res. 2012, 46:1093-1098.
66. Xu B., Karayiorgou M., Gogos J.A. MicroRNAs in psychiatric and neurodevelopmental disorders. Brain Res. 2010, 1338:78-88.
67. Xu Y., Li F., Zhang B., Zhang K., Zhang F., Huang X., et al. MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia. Schizophrenia Res. 2010, 119:219-227.
68. Xu Y., Zhang F., Wang G., Cao3 H., Cheng Z., Shugart Y.Y. plot2groups: an R package to plot scatter points for two groups of values. Source Code Biol. Med. 2014, 9:23.
69. Yang T.P., Beazley C., Montgomery S.B., Dimas A.S., Gutierrez-Arcelus M., Stranger B.E., et al. Genevar: a database and Java application for the analysis and visualization of SNP-gene associations in eQTL studies. Bioinformatics 2010, 26:2474-2476.
70. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 2011, 25:181-213.
71. Yue W.H., Wang H.F., Sun L.D., Tang F.L., Liu Z.H., Zhang H.X., et al. Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat. Genet. 2011, 43:1228-1231.
72. Zhang F., Xu Y., Cao H., Jin C., Cheng Z., Wang G., et al. Mapsnp: an R package to plot a genomic map for single nucleotide polymorphisms. PLoS One 2015, 10:e0123609.